Interpatient variability in dexmedetomidine response: A survey of the literature

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Holliday, Samantha F ^a   Kane Gill, Sandra L ^a   Empey, Philip E ^a   Buckley, Mitchell S ^b   Smithburger, Pamela L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; HYPNOTIC SEDATIVE AGENT;

CRITICAL ILLNESS; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HUMAN; INTENSIVE CARE; METHODOLOGY; PERSONALIZED MEDICINE; REVIEW; STANDARD;

CRITICAL ILLNESS; DEXMEDETOMIDINE; HUMANS; HYPNOTICS AND SEDATIVES; INDIVIDUALIZED MEDICINE; INTENSIVE CARE; POLYMORPHISM, GENETIC;

EID: 84893856342     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/805013     Document Type: Article

References (102)

1. Society of Critical Care Medicine, Communications: critical care statistics. http://www.sccm.org/Communications/Pages/CriticalCareStats.aspx
2. MacLaren R., Forrest L. K., Kiser T. H., Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy 2007 27 3 351 359 2-s2.0-33847327003 10.1592/phco.27.3.351 (Pubitemid 46327903)
3. Ruokonen E., Parviainen I., Jakob S. M., Nunes S., Kaukonen M., Shepherd S. T., Sarapohja T., Bratty J. R., Takala J., Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Medicine 2009 35 2 282 290 2-s2.0-59849087047 10.1007/s00134-008-1296-0
4. Pandharipande P. P., Pun B. T., Herr D. L., Maze M., Girard T. D., Miller R. R., Shintani A. K., Thompson J. L., Jackson J. C., Deppen S. A., Stiles R. A., Dittus R. S., Bernard G. R., Ely E. W., Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. The Journal of the American Medical Association 2007 298 22 2644 2653 2-s2.0-37149040245 10.1001/jama.298.22.2644 (Pubitemid 350254956)
5. Riker R. R., Shehabi Y., Bokesch P. M., Ceraso D., Wisemandle W., Koura F., Whitten P., Margolis B. D., Byrne D. W., Wesley Ely E., Rocha M. G., Dexmedetomidine vs midazolam for sedation of critically Ill patients A randomized trial. The Journal of the American Medical Association 2009 301 5 489 499 2-s2.0-59649127447 10.1001/jama.2009.56
6. Devabhakthuni S., Pajoumand M., Williams C., Kufera J. A., Watson K., Stein D. M., Evaluation of dexmedetomidine: safety and clinical outcomes in critically Ill trauma patients. Journal of Trauma 2011 71 5 1164 1171 2-s2.0-81455133654 10.1097/TA.0b013e3182147670
7. Jakob S. M., Ruokonen E., Grounds R. M., Sarapohja T., Garratt C., Pocock S. J., Bratty J. R., Takala J., Dexmedetomidine vs midazolamor propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. The Journal of the American Medical Association 2012 307 11 1151 1160 2-s2.0-84858657050 10.1001/jama.2012.304
8. Tellor B. R., Arnold H. M., Micek S. T., Kollef M. H., Occurrence and predictors of dexmedetomidine infusion intolerance and failure. Hospital Practice 2012 40 1 186 192
9. Rowe K., Fletcher S., Sedation in the intensive care unit. Continuing Education in Anaesthesia, Critical Care and Pain 2008 8 2 50 55 2-s2.0-41249086238 10.1093/bjaceaccp/mkn005
10. Girard T. D., Kress J. P., Fuchs B. D., Thomason J. W., Schweickert W. D., Pun B. T., Taichman D. B., Dunn J. G., Pohlman A. S., Kinniry P. A., Jackson J. C., Canonico A. E., Light R. W., Shintani A. K., Thompson J. L., Gordon S. M., Hall J. B., Dittus R. S., Bernard G. R., Ely E. W., Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. The Lancet 2008 371 9607 126 134 2-s2.0-38049017332 10.1016/S0140-6736(08)60105-1
11. Barr J., Fraser G. L., Puntillo K., Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical Care Medicine 2013 41 1 263 306
12. Woods J. C., Mion L. C., Connor J. T., Viray F., Jahan L., Huber C., McHugh R., Gonzales J. P., Stoller J. K., Arroliga A. C., Severe agitation among ventilated medical intensive care unit patients: frequency, characteristics and outcomes. Intensive Care Medicine 2004 30 6 1066 1072 2-s2.0-3042693285 10.1007/s00134-004-2193-9 (Pubitemid 38833357)
13. Cohen D., Horiuchi K., Kemper M., Weissman C., Modulating effects of propofol on metabolic and cardiopulmonary responses to stressful intensive care unit procedures. Critical Care Medicine 1996 24 4 612 617 2-s2.0-0029863288 10.1097/00003246-199604000-00011 (Pubitemid 26133795)
14. Devlin J. W., Mallow-Corbett S., Riker R. R., Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Critical Care Medicine 2010 38 6, supplement S231 S243 2-s2.0-77953036827 10.1097/CCM.0b013e3181de125a
15. Weinhouse G. L., Watson P. L., Sedation and sleep disturbances in the ICU. Critical Care Clinics 2009 25 3 539 549 2-s2.0-67649306405 10.1016/j.ccc.2009.04.003
16. Patel S. B., Kress J. P., Sedation and analgesia in the mechanically ventilated patient. American Journal of Respiratory and Critical Care Medicine 2012 185 5 486 497 2-s2.0-84857854451 10.1164/rccm.201102-0273CI
17. Coursin D. B., Coursin D. B., Maccioli G. A., Dexmedetomidine. Current Opinion in Critical Care 2001 7 4 221 226 2-s2.0-0034834555 10.1097/00075198- 200108000-00002 (Pubitemid 32868470)
18. Pandharipande P., Ely E. W., Maze M., Dexmedetomidine for sedation and perioperative management of critically ill patients. Seminars in Anesthesia, Perioperative Medicine and Pain 2006 25 2 43 50 2-s2.0-33744780426 10.1053/j.sane.2006.01.001 (Pubitemid 43833199)
19. Szumita P. M., Baroletti S. A., Anger K. E., Wechsler M. E., Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. American Journal of Health-System Pharmacy 2007 64 1 37 44 2-s2.0-33847337959 10.2146/ajhp050508 (Pubitemid 46395706)
20. Gertler R., Brown H. C., Mitchell D. H., Silvius E. N., Dexmedetomidine: a novel sedative-analgesic agent. Proceedings (Baylor University. Medical Center) 2001 14 1 13 21
21. Murthy T. V. S. P., Singh R., Alpha 2 adrenoceptor agonist- dexmedetomidine role in anaesthesia and intensive care: a clinical review. Journal of Anaesthesiology Clinical Pharmacology 2009 25 3 267 272 2-s2.0-67650519450
22. Panzer O., Moitra V., Sladen R. N., Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Critical Care Clinics 2009 25 3 451 469 2-s2.0-67649354229 10.1016/j.ccc.2009.04.004
23. Bhana N., Goa K. L., McClellan K. J., Dexmedetomidine. Drugs 2000 59 2 263 268 2-s2.0-0034106127 (Pubitemid 30168513)
24. Haselman M. A., Dexmedetomidine: a useful adjunct to consider in some high-risk situations. AANA Journal 2008 76 5 335 339 2-s2.0-53749086162
25. Hoy S. M., Keating G. M., Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 2011 71 11 1481 1501 2-s2.0-79961139017 10.2165/11207190-000000000-00000
26. Gerlach A. T., Dasta J. F., Dexmedetomidine: an updated review. Annals of Pharmacotherapy 2007 41 2 245 254 2-s2.0-33847392052 10.1345/aph.1H314 (Pubitemid 46340055)
27. Mantz J., Josserand J., Hamada S., Dexmedetomidine: new insights. European Journal of Anaesthesiology 2011 28 1 3 6 2-s2.0-79951478264 10.1097/EJA.0b013e32833e266d
28. Yu S. B., Dexmedetomidine sedation in ICU. Korean Journal of Anesthesiology 2012 62 5 405 411
29. Maclaren R., Krisl J. C., Cochrane R. E., Mueller S. W., A case-based approach to the practical application of dexmedetomidine in critically ill adults. Pharmacotherapy 2013 33 2 165 186
30. Maze M., Scarfini C., Cavaliere F., New agents for sedation in the intensive care unit. Critical Care Clinics 2001 17 4 881 897 2-s2.0-0035179223 (Pubitemid 33101686)
31. Venn R. M., Grounds R. M., Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. British Journal of Anaesthesia 2001 87 5 684 690 2-s2.0-0035167022 10.1093/bja/87.5.684 (Pubitemid 33069556)
32. Guinter J. R., Kristeller J. L., Prolonged infusions of dexmedetomidine in critically ill patients. American Journal of Health-System Pharmacy 2010 67 15 1246 1253 2-s2.0-78349247164 10.2146/ajhp090300
33. Khan Z. P., Ferguson C. N., Jones R. M., Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999 54 2 146 165 2-s2.0-0032905215 10.1046/j.1365-2044.1999.00659.x (Pubitemid 29057426)
34. Venn R. M., Bradshaw C. J., Spencer R., Brealey D., Caudwell E., Naughton C., Vedio A., Singer M., Feneck R., Treacher D., Willatts S. M., Grounds R. M., Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999 54 12 1136 1142 2-s2.0-0032705173 10.1046/j.1365-2044.1999.01114.x
35. Tan J. A., Ho K. M., Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Medicine 2010 36 6 926 939 2-s2.0-77954459092 10.1007/s00134-010-1877-6
36. Venn R. M., Hell J., Grounds R. M., Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Critical Care 2000 4 5 302 308 2-s2.0-0033803263 10.1186/cc712
37. Triltsch A. E., Welte M., Von Homeyer P., Große J., Genähr A., Moshirzadeh M., Sidiropoulos A., Konertz W., Kox W. J., Spies C. D., Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Critical Care Medicine 2002 30 5 1007 1014 2-s2.0-0036255632 (Pubitemid 34508021)
38. Talke P., Chen R., Thomas B., Aggarwall A., Gottlieb A., Thorborg P., Heard S., Cheung A., Lee Son S., Kallio A., The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesthesia and Analgesia 2000 90 4 834 839 2-s2.0-0034125510 (Pubitemid 30190786)
39. Smithburger P., Smith R. B., Kane-Gill S. L., Identification of patient predictors for dexmedetomidine effectiveness for ICU sedation. American Journal of Critical Care. In press
40. Kurnik D., Muszkat M., Sofowora G. G., Friedman E. A., Dupont W. D., Scheinin M., Wood A. J. J., Stein C. M., Ethnic and genetic determinants of cardiovascular response to the selective2-adrenoceptor agonist dexmedetomidine. Hypertension 2008 51 2 406 411 2-s2.0-38549107556 10.1161/HYPERTENSIONAHA.107. 098939 (Pubitemid 351159957)
41. Carter B. L., Long T. Y., Cinciripini P. M., A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine and Tobacco Research 2004 6 2 221 227 2-s2.0-2542503580 10.1080/14622200410001676387 (Pubitemid 38678852)
42. Raunio H., Rautio A., Gullstén H., Pelkonen O., Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology 2001 52 4 357 363 2-s2.0-0034792055 10.1046/j.0306-5251.2001.01500.x (Pubitemid 32939440)
43. Park L., Nigg J. T., Waldman I. D., Nummy K. A., Huang-Pollock C., Rappley M., Friderici K. H., Association and linkage of-2A adrenergic receptor gene polymorphisms with childhood ADHD. Molecular Psychiatry 2005 10 6 572 580 2-s2.0-21244434801 10.1038/sj.mp.4001605 (Pubitemid 40897041)
44. Karahalil B., Coskun E., Emerce E., ADRA2A polymorphism and smoking in a Turkish population. Toxicology and Industrial Health 2008 24 3 171 176 2-s2.0-59649105052 10.1177/0748233708093354
45. Kurnik D., Muszkat M., Li C., Sofowora G. G., Friedman E. A., Scheinin M., Wood A. J. J., Stein C. M., Genetic variations in the2A-Adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. Circulation 2011 4 2 179 187 2-s2.0-79959697897 10.1161/CIRCGENETICS.110.957662
46. Iirola T., Aantaa R., Laitio R., Kentala E., Lahtinen M., Wighton A., Garratt C., Ahtola-Sätilä T., Olkkola K. T., Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Critical Care 2011 15 5, article R257 2-s2.0-83155172637 10.1186/cc10518
47. Iirola T., Ihmsen H., Laitio R., Kentala E., Aantaa R., Kurvinen J.-P., Scheinin M., Schwilden H., Schttler J., Olkkola K. T., Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. British Journal of Anaesthesia 2012 108 3 460 468 2-s2.0-84857320674 10.1093/bja/aer441
48. Välitalo P. A., Ahtola-sätilä T., Wighton A., Sarapohja T., Pohjanjousi P., Garratt C., Population pharmacokinetics of dexmedetomidine in critically ill patients. Clinical Drug Investigation 2013 33 8 579 587
49. Invernizzi R. W., Garattini S., Role of presynaptic2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004 28 5 819 827 2-s2.0-4444355123 10.1016/j.pnpbp.2004.05.026 (Pubitemid 39195273)
50. Yanpallewar S. U., Fernandes K., Marathe S. V., Vadodaria K. C., Jhaveri D., Rommelfanger K., Ladiwala U., Jha S., Muthig V., Hein L., Bartlett P., Weinshenker D., Vaidya V. A.,2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. Journal of Neuroscience 2010 30 3 1096 1109 2-s2.0-75749091846 10.1523/JNEUROSCI.2309-09.2010
51. Sallinen J., Höglund I., Engström M., Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. British Journal of Pharmacology 2007 150 4 391 402 (Pubitemid 46280650)
52. Dwyer J. M., Platt B. J., Sukoff Rizzo S. J., Pulicicchio C. M., Wantuch C., Zhang M.-Y., Cummons T., Leventhal L., Bender C. N., Zhang J., Kowal D., Lu S., Rajarao S. J. R., Smith D. L., Shilling A. D., Wang J., Butera J., Resnick L., Rosenzweig-Lipson S., Schechter L. E., Beyer C. E., Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective2A-adrenoceptor antagonism. International Journal of Neuropsychopharmacology 2010 13 9 1193 1205 2-s2.0-77957227893 10.1017/S1461145709991088
53. Lee S., Kim B. H., Lim K., Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects. Journal of Clinical Pharmacology and Therapeutics 2012 37 6 698 703
54. Kaivosaari S., Toivonen P., Aitio O., Sipilä J., Koskinen M., Salonen J. S., Finel M., Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metabolism and Disposition 2008 36 8 1529 1537 2-s2.0-47949097984 10.1124/dmd.108.021709
55. De Wolf A. M., Fragen R. J., Avram M. J., Fitzgerald P. C., Rahimi-Danesh F., The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesthesia and Analgesia 2001 93 5 1205 1209 2-s2.0-0034761921 (Pubitemid 33021018)
56. Angst M. S., Ramaswamy B., Davies M. F., Maze M., Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology 2004 101 3 744 752 2-s2.0-4344662340 10.1097/00000542-200409000-00024 (Pubitemid 39121655)
57. Ebert T. J., Hall J. E., Barney J. A., Uhrich T. D., Colinco M. D., The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000 93 2 382 394 2-s2.0-0033860761 (Pubitemid 30620311)
58. Kallio A., Scheinin M., Koulu M., Ponkilainen R., Ruskoaho H., Viinamaki O., Scheinin H., Effects of dexmedetomidine, a selective2-adrenoceptor agonist, on hemodynamic control mechanisms. Clinical Pharmacology and Therapeutics 1989 46 1 33 42 2-s2.0-0024352049 (Pubitemid 19195772)
59. Belleville J. P., Ward D. S., Bloor B. C., Maze M., Effects of intravenous dexmedetomidine in humans: I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992 77 6 1125 1133 2-s2.0-0026621830 (Pubitemid 23001123)
60. Dutta S., Lal R., Karol M. D., Cohen T., Ebert T., Influence of cardiac output on dexmedetomidine pharmacokinetics. Journal of Pharmaceutical Sciences 2000 89 4 519 527
61. Power B. M., Forbes A. M., Van Heerden P. V., Ilett K. F., Pharmacokinetics of drugs used in critically ill adults. Clinical Pharmacokinetics 1998 34 1 25 56 2-s2.0-0031985566 10.2165/00003088-199834010- 00002 (Pubitemid 28041091)
62. Choi L., Caffo B. S., Kohli U., Pandharipande P., Kurnik D., Ely E. W., Stein C. M., A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2011 38 5 613 636 2-s2.0-80053207197 10.1007/s10928-011-9211-7
63. Venn R. M., Karol M. D., Grounds R. M., Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. British Journal of Anaesthesia 2002 88 5 669 675 2-s2.0-0036257713 10.1093/bja/88.5.669 (Pubitemid 34498595)
64. Dasta J. F., Kane-Gill S. L., Durtschi A. J., Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Annals of Pharmacotherapy 2004 38 7-8 1130 1135 2-s2.0-3042645548 10.1345/aph.1D615 (Pubitemid 38802147)
65. Jones G. M., Murphy C. V., Gerlach A. T., Goodman E. M., Pell L. J., High-dose dexmedetomidine for sedation in the intensive care unit: an evaluation of clinical efficacy and safety. Annals of Pharmacotherapy 2011 45 6 740 747 2-s2.0-79958783407 10.1345/aph.1P726
66. Inui N., CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6). Atlas of Genetics and Cytogenetics in Oncology and Haematology 2011 9 875 877
67. Nakajima M., Fukami T., Yamanaka H., Higashi E., Sakai H., Yoshida R., Kwon J.-T., McLeod H. L., Yokoi T., Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clinical Pharmacology and Therapeutics 2006 80 3 282 297 2-s2.0-33748151442 10.1016/j.clpt.2006.05.012 (Pubitemid 44313906)
68. Schoedel K. A., Hoffmann E. B., Rao Y., Sellers E. M., Tyndale R. F., Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004 14 9 615 626 2-s2.0-4644255903 10.1097/00008571-200409000-00006 (Pubitemid 39281816)
69. Kohli U., Pandharipande P., Muszkat M., CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology 2012 68 6 937 942
70. Yaar S., Yavaş S., Karahalil B., The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Molecular Biology Reports 2011 38 5 3383 3389 2-s2.0-80052483095 10.1007/s11033-010-0446-y
71. Kohli U., Muszkat M., Sofowora G. G., Harris P. A., Friedman E. A., Dupont W. D., Scheinin M., Wood A. J. J., Stein C. M., Kurnik D., Effects of variation in the human2A- and2C-adrenoceptor genes on cognitive tasks and pain perception. European Journal of Pain 2010 14 2 154 159 2-s2.0-74749090954 10.1016/j.ejpain.2009.04.003
72. Muszkat M., Sofowora G. G., Xie H.-G., Wood A. J. J., Stein C. M.,2B Adrenergic receptor 301-303 deletion polymorphism and vascular2 adrenergic receptor response. Pharmacogenetics and Genomics 2005 15 1 23 28 2-s2.0-20644459848 (Pubitemid 43205523)
73. Muszkat M., Kurnik D., Sofowora G. G., Wood A. J. J., Stein C. M., Independent regulation of1 and2 adrenergic receptor-mediated vasoconstriction in vivo. Journal of Hypertension 2011 29 2 251 256 2-s2.0-78651310335 10.1097/HJH.0b013e3283407ffd
74. Kaivosaari S., Finel M., Koskinen M., N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 2011 41 8 652 669 2-s2.0-79960140023 10.3109/00498254.2011.563327
75. Bock K. W., Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochemical Pharmacology 2010 80 6 771 777 2-s2.0-77954762075 10.1016/j.bcp.2010.04.034
76. Court M. H., Duan S. X., Von Moltke L. L., Greenblatt D. J., Patten C. J., Miners J. O., Mackenzie P. I., Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. Journal of Pharmacology and Experimental Therapeutics 2001 299 3 998 1006 2-s2.0-0035197725 (Pubitemid 33104971)
77. Hakooz N., Alzubiedi S., Yousef A.-M., Arafat T., Dajani R., Ababneh N., Ismail S., UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. Molecular Biology Reports 2012 39 7 7763 7768 2-s2.0-84857272640 10.1007/s11033-012-1615-y
78. Chatzistefanidis D., Georgiou I., Kyritsis A. P., Markoula S., Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics 2012 13 9 1055 1071
79. López M., Dorado P., Monroy N., ElisaAlonso M., Jung-Cook H., MacHín E., Peñas-Lledó E., Llerena A., Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabolism and Drug Interactions 2011 26 1 5 12 2-s2.0-79956340310 10.1515/DMDI.2011.008
80. Erickson-Ridout K. K., Zhu J., Lazarus P., Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenetics and Genomics 2011 21 9 539 551 2-s2.0-80051792894 10.1097/FPC.0b013e328348c76b
81. Berg J. Z., Von Weymarn L. B., Thompson E. A., Wickham K. M., Weisensel N. A., Hatsukami D. K., Murphy S. E., UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiology Biomarkers and Prevention 2010 19 6 1423 1431 2-s2.0-77953319366 10.1158/1055-9965.EPI-09-0959
82. Ehmer U., Vogel A., Schütte J. K., Krone B., Manns M. P., Strassburg C. P., Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004 39 4 970 977 2-s2.0-1842532189 10.1002/hep.20131 (Pubitemid 38428936)
83. Wiener D., Fang J.-L., Dossett N., Lazarus P., Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Research 2004 64 3 1190 1196 2-s2.0-0842325733 10.1158/0008-5472.CAN-03-3219 (Pubitemid 38176928)
84. Kato Y., Izukawa T., Oda S., Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metabolism and Disposition 2013 41 7 1389 1397
85. Belfer I., Buzas B., Hipp H., Phillips G., Taubman J., Lorincz I., Evans C., Lipsky R. H., Enoch M.-A., Max M. B., Goldman D., Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. Journal of Human Genetics 2005 50 1 12 20 2-s2.0-13844262850 10.1007/s10038-004-0211-y (Pubitemid 40248310)
86. Westfall T. C., Brunton L. L., Chabner B. A., Knollmann B. C., Chapter 8: neurotransmission: the autonomic and somatic motor nervous systems. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011 12th New York, NY, USA McGraw-Hill
87. Maze M., Fujinaga M.,2 Adrenoceptors in pain modulation: which subtype should be targeted to produce analgesia? Anesthesiology 2000 92 4 934 936 2-s2.0-0033625186 (Pubitemid 30180967)
88. Kurnik D., Muszkat M., Li C., Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clinical Pharmacology and Therapeutics 2006 79 3 173 185
89. Lario S., Calls J., Cases A., Oriola J., Torras A., Rivera F., MspI identifies a biallelic polymorphism in the promoter region of the(2A)-adrenergic receptor gene. Clinical Genetics 1997 51 2 129 130 2-s2.0-0030932778 (Pubitemid 27149724)
90. Stevenson J., Langley K., Pay H., Payton A., Worthington J., Ollier W., Thapar A., Attention deficit hyperactivity disorder with reading disabilities: preliminary genetic findings on the involvement of the ADRA2A gene. Journal of Child Psychology and Psychiatry and Allied Disciplines 2005 46 10 1081 1088 2-s2.0-33644683216 10.1111/j.1469-7610.2005.01533.x (Pubitemid 44192654)
91. Sickert L., Müller D. J., Tiwari A. K., Shaikh S., Zai C., De Souza R., De Luca V., Meltzer H. Y., Lieberman J. A., Kennedy J. L., Association of the2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009 10 7 1169 1176 2-s2.0-70449510603 10.2217/pgs.09.43
92. Wakeno M., Kato M., Okugawa G., Fukuda T., Hosoi Y., Takekita Y., Yamashita M., Nonen S., Azuma J., Kinoshita T., The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Journal of Clinical Psychopharmacology 2008 28 5 518 524 2-s2.0-58149139155 10.1097/JCP.0b013e31818455fc
93. Aleong R. G., Sauer W. H., Robertson A. D., Liggett S. B., Bristow M. R., Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circulation 2013 6 1 137 143
94. Savva J., Alfakih K., Galloway S. L., Hall A. S., West R. M., Ball S. G., Balmforth A. J., Maqbool A., The2C-Del322-325 adrenoceptor polymorphism and the occurrence of left ventricular hypertrophy in hypertensives. Blood Pressure 2012 21 2 116 121 2-s2.0-84859067882 10.3109/08037051.2011.622988
95. Bristow M. R., Murphy G. A., Krause-Steinrauf H., Anderson J. L., Carlquist J. F., Thaneemit-Chen S., Krishnan V., Abraham W. T., Lowes B. D., Port J. D., Davis G. W., Lazzeroni L. C., Robertson A. D., Lavori P. W., Liggett S. B., An2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the β -Blocker Bucindolol in chronic heart failure. Circulation 2010 3 1 21 28 2-s2.0-76549133595 10.1161/CIRCHEARTFAILURE.109.885962
96. Heinonen P., Koulu M., Pesonen U., Karvonen M. K., Rissanen A., Laakso M., Valve R., Uusitupa M., Scheinin M., Identification of a three-amino acid deletion in the2b-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. Journal of Clinical Endocrinology & Metabolism 1999 84 7 2429 2433 2-s2.0-0033305789
97. Baldwin C. T., Schwartz F., Baima J., Burzstyn M., DeStefano A. L., Gavras I., Handy D. E., Joost O., Martel T., Manolis A., Nicolaou M., Bresnahan M., Farrer L., Gavras H., Identification of a polymorphic glutamic acid stretch in the(2B)- adrenergic receptor and lack of linkage with essential hypertension. American Journal of Hypertension 1999 12 9 I 853 857 2-s2.0-0032888488 10.1016/S0895-7061(99)00070-9 (Pubitemid 29469937)
98. Ueno L. M., Frazzatto E. S. T., Batalha L. T., Trombetta I. C., Do Socorro Brasileiro M., Irigoyen C., Brum P. C., Villares S. M. F., Negrão C. E.,2B-Adrenergic receptor deletion polymorphism and cardiac autonomic nervous system responses to exercise in obese women. International Journal of Obesity 2006 30 2 214 220 2-s2.0-32544433039 10.1038/sj.ijo.0803140 (Pubitemid 43237673)
99. Etzel J. P., Rana B. K., Wen G., Farmer R. J., Schork N. J., O'Connor D. T., Insel P. A., Genetic variation at the human2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Hypertension 2005 45 6 1207 1213 2-s2.0-20044388350 10.1161/01.HYP.0000166721.42734.49 (Pubitemid 40770328)
100. Suzuki N., Matsunaga T., Nagasumi K., Yamamura T., Shihara N., Moritani T., Ue H., Fukushima M., Tamon A., Seino Y., Tsuda K., Yasuda K.,2b-Adrenergic receptor deletion polymorphism associates with autonomic nervous system activity in young healthy Japanese. Journal of Clinical Endocrinology & Metabolism 2003 88 3 1184 1187 2-s2.0-0037342020 10.1210/jc.2002-021190 (Pubitemid 36337775)
101. Small K. M., Brown K. M., Forbes S. L., Liggett S. B., Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. The Journal of Biological Chemistry 2001 276 7 4917 4922 2-s2.0-0035895936 10.1074/jbc.M008118200
102. Posti J. P., Valve L., Ruohonen S., Akkila J., Scheinin M., Snapir A., Dorsal hand vein responses to the1-adrenoceptor agonist phenylephrine do not predict responses to the2-adrenoceptor agonist dexmedetomidine. European Journal of Pharmacology 2011 653 1-3 70 74 2-s2.0-78651517512 10.1016/j.ejphar.2010.11. 024